Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease

Journal of Physiology

Volumn 590, Issue 22, 2012, Pages 5845-5860

  Kiriazis, Helen ^a   Jennings, Nicole L ^a   Davern, Pamela ^a   Lambert, Gavin ^a,b   Su, Yidan ^a   Pang, Terence ^d   Du, Xin ^d   La Greca, Luisa ^a   Head, Geoffrey A ^a,c   Hannan, Anthony J ^d   Du, Xiao Jun ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; NORADRENALIN; PROTEIN C FOS;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC DYSFUNCTION; BRADYCARDIA; BRAIN REGION; CELL SIZE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART MUSCLE; HEART RATE; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RR INTERVAL; SUDDEN DEATH; TACHYCARDIA; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; ATRIAL FIBRILLATION; ATROPINE; AUTONOMIC NERVOUS SYSTEM; BRADYCARDIA; DEATH, SUDDEN; DISEASE MODELS, ANIMAL; HEART; HEART RATE; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; NEURONS; NOREPINEPHRINE; TACHYCARDIA;

EID: 84869785257     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2012.238113     Document Type: Article

References (58)

1. Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT, Przuntek H & Agelink MW (2002). Autonomic nervous system function in Huntington's disease. J Neurol Neurosurg Psychiatry 72, 726-731.
2. Arora R, Ulphani JS, Villuendas R, Ng J, Harvey L, Thordson S, Inderyas F, Lu Y, Gordon D, Denes P, Greene R, Crawford S, Decker R, Morris A, Goldberger J & Kadish AH (2008). Neural substrate for atrial fibrillation: implications for targeted parasympathetic blockade in the posterior left atrium. Am J Physiol Heart Circ Physiol 294, H134-H144.
3. Aziz NA, Anguelova GV, Marinus J, van Dijk JG & Roos RA (2010). Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease. Eur J Neurol 17, 1068-1074.
4. Aziz NA, Pijl H, Frolich M, Schroder-van der Elst JP, van der Bent C, Roelfsema F & Roos RA (2009). Delayed onset of the diurnal melatonin rise in patients with Huntington's disease. J Neurol 256, 1961-1965.
5. Bar KJ, Boettger MK, Andrich J, Epplen JT, Fischer F, Cordes J, Koschke M & Agelink MW (2008). Cardiovagal modulation upon postural change is altered in Huntington's disease. Eur J Neurol 15, 869-871.
6. Bates GP (2005). History of genetic disease: the molecular genetics of Huntington disease - a history. Nat Rev Genet 6, 766-773.
7. Bates GP, Mangiarini L, Mahal A & Davies SW (1997). Transgenic models of Huntington's disease. Hum Mol Genet 6, 1633-1637.
8. Billman GE (2006). A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: implications for future anti-arrhythmic drug development. Pharmacol Ther 111, 808-835.
9. 2+ fluorescence studies using fura-2 AM in the isolated innervated beating rabbit heart. Exp Physiol 95, 80-92.
10. Chen LS, Zhou S, Fishbein MC & Chen PS (2007). New perspectives on the role of autonomic nervous system in the genesis of arrhythmias. J Cardiovasc Electrophysiol 18, 123-127.
11. Chen PS & Tan AY (2007). Autonomic nerve activity and atrial fibrillation. Heart Rhythm 4, S61-S64.
12. Chiu E & Alexander L (1982). Causes of death in Huntington's disease. Med J Aust 1, 153.
13. Dampney RA (1994). Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 74, 323-364.
14. Dampney RA, Li YW, Hirooka Y, Potts P & Polson JW (1995). Use of c-fos functional mapping to identify the central baroreceptor reflex pathway: advantages and limitations. Clin Exp Hypertens 17, 197-208.
15. Davern PJ, Chen D, Head GA, Chavez CA, Walther T & Mayorov DN (2009). Role of angiotensin II Type 1A receptors in cardiovascular reactivity and neuronal activation after aversive stress in mice. Hypertension 54, 1262-1268.
16. Davern PJ & Head GA (2007). Fos-related antigen immunoreactivity after acute and chronic angiotensin II-induced hypertension in the rabbit brain. Hypertension 49, 1170-1177.
17. Davern PJ & Head GA (2011). Role of the medial amygdala in mediating responses to aversive stimuli leading to hypertension. Clin Exp Pharmacol Physiol 38, 136-143.
18. Davern PJ, Jackson KL, Nguyen-Huu TP, La Greca L & Head GA (2010). Cardiovascular responses to aversive and nonaversive stressors in Schlager genetically hypertensive mice. Am J Hypertens 23, 838-844.
19. Den Heijer JC, Bollen WL, Reulen JP, van Dijk JG, Kramer CG, Roos RA & Buruma OJ (1988). Autonomic nervous function in Huntington's disease. Arch Neurol 45, 309-312.
20. Du XJ, Cox HS, Dart AM & Esler MD (1999). Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure. Cardiovasc Res 43, 919-929.
21. 2-adrenergic receptors in the heart. Cardiovasc Res 48, 448-454.
22. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS & Esler MD (1996). Cardiac sympathetic nerve function in congestive heart failure. Circulation 93, 1667-1676.
23. Furukawa Y, Hoyano Y & Chiba S (1996). Parasympathetic inhibition of sympathetic effects on sinus rate in anesthetized dogs. Am J Physiol Heart Circ Physiol 271, H44-H50.
24. Gil JM & Rego AC (2009). The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res Rev 59, 410-431.
25. Griffioen KJ, Wan R, Brown TR, Okun E, Camandola S, Mughal MR, Phillips TM & Mattson MP (2012). Aberrant heart rate and brainstem brain-derived neurotrophic factor (BDNF) signaling in a mouse model of Huntington's disease. Neurobiol Aging 33, 1481.e1-1481.e5.
26. Himura Y, Felten SY, Kashiki M, Lewandowski TJ, Delehanty JM & Liang CS (1993). Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 88, 1299-1309.
27. Horiuchi J, McAllen RM, Allen AM, Killinger S, Fontes MA & Dampney RA (2004). Descending vasomotor pathways from the dorsomedial hypothalamic nucleus: role of medullary raphe and RVLM. Am J Physiol Regul Integr Comp Physiol 287, R824-R832.
28. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G & Esler MD (1994). Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 23, 570-578.
29. Kobal J, Meglic B, Mesec A & Peterlin B (2004). Early sympathetic hyperactivity in Huntington's disease. Eur J Neurol 11, 842-848.
30. Kudo T, Schroeder A, Loh DH, Kuljis D, Jordan MC, Roos KP & Colwell CS (2011). Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease. Exp Neurol 228, 80-90.
31. Lambert GW & Jonsdottir IH (1998). Influence of voluntary exercise on hypothalamic norepinephrine. J Appl Physiol 85, 962-966.
32. Lanska DJ, Lavine L, Lanska MJ & Schoenberg BS (1988). Huntington's disease mortality in the United States. Neurology 38, 769-772.
33. Leung RS (2009). Sleep-disordered breathing: autonomic mechanisms and arrhythmias. Prog Cardiovasc Dis 51, 324-338.
34. Liang CS, Frantz RP, Suematsu M, Sakamoto S, Sullebarger JT, Fan TM & Guthinger L (1991). Chronic β-adrenoceptor blockade prevents the development of β-adrenergic subsensitivity in experimental right-sided congestive heart failure in dogs. Circulation 84, 254-266.
35. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW & Bates GP (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
36. Mihm MJ, Amann DM, Schanbacher BL, Altschuld RA, Bauer JA & Hoyt KR (2007). Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 25, 297-308.
37. Morady F, Kou WH, Nelson SD, de Buitleir M, Schmaltz S, Kadish AH, Toivonen LK & Kushner JA (1988). Accentuated antagonism between β-adrenergic and vagal effects on ventricular refractoriness in humans. Circulation 77, 289-297.
38. Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA & Maywood ES (2005). Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci 25, 157-163.
39. Munoz-Sanjuan I & Bates GP (2011). The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest 121, 476-483.
40. Olshansky B, Sabbah HN, Hauptman PJ & Colucci WS (2008). Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 118, 863-871.
41. Pang TY, Du X, Zajac MS, Howard ML & Hannan AJ (2009). Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum Mol Genet 18, 753-766.
42. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R & Robbins J (2008). Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation 117, 2743-2751.
43. Pretorius L, Du XJ, Woodcock EA, Kiriazis H, Lin RC, Marasco S, Medcalf RL, Ming Z, Head GA, Tan JW, Cemerlang N, Sadoshima J, Shioi T, Izumo S, Lukoshkova EV, Dart AM, Jennings GL & McMullen JR (2009). Reduced phosphoinositide 3-kinase (p110α) activation increases the susceptibility to atrial fibrillation. Am J Pathol 175, 998-1009.
44. Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, Salama G, McTiernan CF & London B (2005). Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-α. Am J Physiol Heart Circ Physiol 289, H1456-H1467.
45. Sah VP, Minamisawa S, Tam SP, Wu TH, Dorn GW 2nd, Ross J Jr, Chien KR & Brown JH (1999). Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest 103, 1627-1634.
46. Sassone J, Colciago C, Cislaghi G, Silani V & Ciammola A (2009). Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 219, 385-397.
47. Schauerte P, Scherlag BJ, Pitha J, Scherlag MA, Reynolds D, Lazzara R & Jackman WM (2000). Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 102, 2774-2780.
48. Schroeder AM, Loh DH, Jordan MC, Roos KP & Colwell CS (2011). Baroreceptor reflex dysfunction in the BACHD mouse model of Huntington's disease. PLoS Curr 3, RRN1266.
49. Schwartz PJ, La Rovere MT & Vanoli E (1992). Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 85, I77-I91.
50. Sharma KR, Romano JG, Ayyar DR, Rotta FT, Facca A & Sanchez-Ramos J (1999). Sympathetic skin response and heart rate variability in patients with Huntington disease. Arch Neurol 56, 1248-1252.
51. Sorensen SA & Fenger K (1992). Causes of death in patients with Huntington's disease and in unaffected first degree relatives. J Med Genet 29, 911-914.
52. Steele AD, Jackson WS, King OD & Lindquist S (2007). The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. Proc Natl Acad Sci U S A 104, 1983-1988.
53. Stober T, Sen S & Burger L (1983). Bradycardia and second-degree AV block: an expression of the dominance of cholinergic activity in the rigid form of Huntington's disease. J Neurol 229, 129-132.
54. Tan AY, Zhou S, Ogawa M, Song J, Chu M, Li H, Fishbein MC, Lin SF, Chen LS & Chen PS (2008). Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation 118, 916-925.
55. Tan TP, Gao XM, Krawczyszyn M, Feng X, Kiriazis H, Dart AM & Du XJ (2003). Assessment of cardiac function by echocardiography in conscious and anesthetized mice: importance of the autonomic nervous system and disease state. J Cardiovasc Pharmacol 42, 182-190.
56. van der Burg JM, Bjorkqvist M & Brundin P (2009). Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 8, 765-774.
57. Videnovic A, Leurgans S, Fan W, Jaglin J & Shannon KM (2009). Daytime somnolence and nocturnal sleep disturbances in Huntington disease. Parkinsonism Relat Disord 15, 471-474.
58. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC Jr, Kasi VS, Hoit BD, Keshelava G, Zhao H, Capecchi MR & Bernstein KE (2004). Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165, 1019-1032.